Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Epinastine + pseudoephedrine is a combination of two pharmaceutical agents used primarily for the symptomatic treatment of allergic conditions involving nasal and ocular symptoms. Epinastine is an H1 histamine receptor antagonist that prevents the effects of histamine, thereby reducing allergic symptoms such as itching, particularly in allergic conjunctivitis[3][6]. Pseudoephedrine is a sympathomimetic agent that acts as an alpha- and beta-adrenergic agonist, leading to vasoconstriction in the nasal mucosa and resulting in relief from nasal congestion[2][7]. The combination targets both ocular and nasal symptoms associated with allergies or upper respiratory tract infections.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on epinastine + pseudoephedrine.